FINNENCE ▪ THE WIRE FILE
THE WIRE · № 72590
News■ Mixed
TRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertension
KINDNews
DIRECTION■ Mixed
SOURCES6
ENTITIES3
STORY SIZE6 RECORDS
FIRST SEEN2026-10-09 07:54 UTC
LAST UPDATE2026-10-09 18:28 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Two biotech IPOs pricing shows selective reopening of biotech primary markets.
Biotech IPO window selectively reopening
CATALYST TO WATCH
Post-IPO trading performance
MAIN RISK
Weak aftermarket could chill issuance
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 6 TIMES · FIRST 2026-10-09 07:54 UTC · LAST 2026-10-09 18:28 UTC2026-10-09 07:54 UTCNewsTRexBio prices $117M IPO for Tregs as Retension lands $45M Nasdaq debut for hypertensionCURRENT RECORD
2026-10-09 08:00 UTCNewsPrifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara's Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD
2026-10-09 14:15 UTCNewsCity Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut
2026-10-09 16:03 UTCNewsEli Lilly-Backed Biotech TRex Dips 3.6% After $116.7 Million IPO
2026-10-09 17:48 UTCNewsTRex prices IPO at bottom of range as Retension makes its public debut
2026-10-09 18:28 UTCNewsTRrexBio’s IPO Bags $116M to Bring the Immune System Back Into Balance
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares IBB, XBI, Healthcare
Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara's Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD2026-10-09 08:00 UTC
Prifemilast Demonstrates Superior Efficacy vs. Apremilast in Newsoara's Head-to-Head Phase 3 Psoriasis Trial; cAMPfield Advancing the Potential Best-in-Class Oral PDE4 Inhibitor in IBD2026-10-09 08:00 UTC
→CORRELATIONshares XBI, Healthcare
Lilly-backed TRex rakes in $117M IPO, while hypertension biotech Retension reveals $45M listing2026-10-09 08:29 UTC
Lilly-backed TRex rakes in $117M IPO, while hypertension biotech Retension reveals $45M listing2026-10-09 08:29 UTC
→CORRELATIONshares Healthcare
The Cigna Group's Third Quarter 2026 Earnings Release Details2026-10-09 10:00 UTC
The Cigna Group's Third Quarter 2026 Earnings Release Details2026-10-09 10:00 UTC
→CORRELATIONshares Healthcare
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity2026-10-09 10:45 UTC
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity2026-10-09 10:45 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.